Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients.

Apolipoprotein M (APOM) is a plasma apolipoprotein closely involved with lipid metabolism and inflammation. In vitro studies suggest that APOM may also have a tumor-suppressive role in breast cancer. In the present study, we aimed to evaluate the impact of plasma APOM levels on the prognosis of breast cancer patients. We measured APOM levels using an enzyme-linked immunosorbent assay in 75 patients with ER-positive/HER2-negative metastatic breast cancer. The endpoint was overall survival (OS) at 24 months. During the 24-month follow-up period, 34.7% of the patients died. Baseline APOM levels were significantly reduced in patients who deceased during follow-up compared to survivors (42.7 ± 14.5 µg/mL versus 52.2 ± 13.8 µg/mL; P = 0.003). Cox regression analysis showed a hazard ratio of 0.30 [95% confidence interval 0.15-0.61]; P < 0.001 per doubling of APOM levels. Correction for age, C-reactive protein, menopausal state, histology of the primary tumor, metastatic site, number of metastases, endocrine resistance, scheduled therapy line, and kind of scheduled therapy indicated that circulating APOM predicted OS independently of these parameters (HRper doubling = 0.23 [0.09-0.56; P = 0.001). Our study suggests that circulating APOM is significantly linked with reduced mortality in metastatic breast cancer patients. © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.]

Citation

Axel Muendlein, Christine Heinzle, Eva Maria Brandtner, Andreas Leiherer, Kathrin Geiger, Stella Gaenger, Heinz Drexel, Tobias Dechow, Thomas Decker. Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients. Breast cancer research and treatment. 2023 Oct;201(3):571-576

Mesh Tags

Substances

PMID: 37490173

search → result